Immunogen reached a licensing deal with Takeda that gives the Japan-based drug maker exclusive rights to use the U.S. biotech firm’s technology to develop cancer therapies for up to two undisclosed targets.
from WSJ.com: US Business http://ift.tt/1LNA5WI
via IFTTT
from WSJ.com: US Business http://ift.tt/1LNA5WI
via IFTTT
No comments:
Post a Comment